Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04590508 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease
A Phase 2 study of Crohn Disease, sponsored by National University of Natural Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04590508: Active Phase 2 study of Crohn Disease, sponsored by National University of Natural Medicine.
NCT04590508 is a Phase 2 study of Crohn Disease that is active but no longer recruiting, run by National University of Natural Medicine. The registered enrollment target is 20 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04590508, a Phase 2 study of Crohn Disease, is active but no longer recruiting, sponsored by National University of Natural Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A pilot study to assess the safety and tolerability of an orally administered natural product derived from hops, called xanthohumol, in humans with Crohn's Disease, in order to identify a biological signature of xanthohumol exposure, and to characterize the role of xanthohumol metabolism by intestinal microorganisms in that signature within adults with Crohn's Disease.
Primary Outcome
Aspartate aminotransferase is an enzyme that is often measured in blood as an indication of liver toxicity. Reported as: % abnormal, % new abnormals, and mean change from baseline.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Xanthohumol
Study Locations (1)
Oregon
- National University of Natural Medicine - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2025-07-30 |
| Phase | Phase 2 |
What the registry record for NCT04590508 still lists
NCT04590508 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04590508 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT04590508 about?
NCT04590508 is a clinical study titled "A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease". A pilot study to assess the safety and tolerability of an orally administered natural product derived from hops, called xanthohumol, in humans with Crohn's Disease, in order to identify a biological signature of xanthohumol exposure, and to characterize the role of xanthohumol metabolism by intestin...
What is the current status of trial NCT04590508?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-10-01. Estimated completion is 2025-07-30.
What conditions does trial NCT04590508 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT04590508?
The interventions under investigation include: Placebo (OTHER), Xanthohumol (DRUG).
Who is sponsoring clinical trial NCT04590508?
This trial is sponsored by National University of Natural Medicine, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04590508 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04590508's enrollment target sits among peer trials
20 63rd of 71 higher than 7 of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Standardized Microbiota Transplant Therapy in Crohn's Disease
RECRUITING · Phase 2
-
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Precise Infliximab Exposure and Pharmacodynamic Control
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant for Crohn's Disease
RECRUITING · Phase 2
-
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI